If irritation persists, reduce usage or discontinue
Rigorous, adequately powered randomised controlled trials, with standardised background therapy, longitudinal biomarker sampling, and patient-reported outcomes, are now needed to determine efficacy, optimal candidates, and durability of response
These include rapid weight reduction, alterations in metabolic hormones, changes in insulin sensitivity, and shifts in adipose tissue distribution
GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP receptor agonists (tirzepatide) do not directly cause muscle wasting
Unlike full-length hGH, AOD-9604 does not bind the growth hormone receptor and has shown no measurable effect on IGF-1 levels, glucose homeostasis, or somatic growth in the published preclinical literature